Clinical trials: Carcinomas
Renal Cell Carcinoma, Kidney Cancer
Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
The goal of this clinical research study is to learn if bevacizumab (Avastin®) can control metastatic renal cell carcinoma (RCC). The safety of the treatment will also be studied. Objectives: Primary: 1.
- Trial name
- NCT00113217
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Intraepithelial Neoplasia
Genotypification and Predisposing Factors in Human Papilloma Virus Infection
Objective: Determine the genotypes and risk factors associated with human papilloma virus infection in Mexican women. Methods: It was a cross-sectional study of women attended at the Materno-Perinatal Hospital "Mónica Pretelini"…
- Trial name
- HPV (NCT01924117)
- Testing
- Linear Array HPV Genotyping assay
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Materno-Perinatal Hospital of the State of Mexico
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer
This phase I trial is studying the side effects and best dose of gemcitabine when given together with radiation therapy and cisplatin in treating patients with cervical cancer that has not spread beyond the pelvis.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT00068549
- Testing
- Gemcitabine Hydrochloride, Cisplatin, Radiation Therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Gynecologic Oncology Group
Non-small Cell Lung Cancer, Aquired Resistance
Acquired Resistant Mechanism of the First-generation EGFR TKIs
Patients with advanced non-small-cell lung cancer (NSCLC) harboring sensitive epithelial growth factor receptor (EGFR) mutations invariably develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs).
- Conditions
- Non-small Cell Lung Cancer, Aquired Resistance, EGFR TKIs
- Trial name
- NCT02804217
- Testing
- Genetic: mutation profile
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinical Trial
This clinical trial aims to systematically evaluate the clinical performance and accuracy of the HepaAiQ test kit, a multi-gene methylation assay based on PCR with fluorescent probe detection.
- Trial name
- NCT06842563
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Singlera Genomics Inc.
Gastric Neuroendocrine Carcinoma (G-NEC), Postoperative Adjuvant Therapy for G-NEC
ML Decision Model for G-NEC Adjuvant Therapy
Gastric neuroendocrine carcinoma (G-NEC) is a rare and aggressive tumor originating from neuroendocrine cells in the stomach lining. It is characterized by a high propensity for recurrence and a generally poor prognosis.
- Conditions
- Gastric Neuroendocrine Carcinoma (G-NEC), Postoperative Adjuvant Therapy for G-NEC, Survival Outcomes, Machine Learning
- Trial name
- G-NEC (NCT06663852)
- Where
- China
- Volunteers
- 1,505 people
- Sponsor
- Chang-Ming Huang, Prof.
Prostate Cancer (Adenocarcinoma)
A Correlative Study of Biomarkers of Resistance in Patients With Castrate Resistant Prostate Cancer Treated With Abiraterone
Adrenal androgens are serum biomarkers of interest that may help guide abiraterone acetate treatment, particularly at the time of progression.
- Trial name
- NCT01857908
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Nasopharyngeal Carcinoma
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
This study is a randomized, double-blind, multi-center phase III clinical study to compare the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with chemotherapy in the first-line treatment of…
- Trial name
- NCT04974398
- Testing
- Penpulimab
- Where
- 56 sites in United States, Australia and 3 more
- Volunteers
- 296 people
- Sponsor
- Akeso
Non-small Cell Lung Cancer
Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients
Evaluate the efficacy and safety of Monosialoganglioside(GM1) to prevent the neurotoxicity induced by cisplatin
- Trial name
- NCT01882621
- Testing
- Monosialoganglioside(GM1), normal saline
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
Escalating Doses of Oxaliplatin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Children and Adolescents With Extensive Colon Carcinoma
The goal of this clinical research study is to find the highest tolerated dose of heated intra-abdominal oxaliplatin that can be given to patients with colon cancer.
- Trial name
- NCT02062749
- Testing
- Oxaliplatin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Colon Cancer, Gastric Cancer
A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies
A randomized control trial to evaluate the feasibility of implementing a patient educational platform (PEP) for patients with gastrointestinal malignancies undergoing active chemotherapy treatment.
- Conditions
- Colon Cancer, Gastric Cancer, Pancreas Cancer, Rectal Cancer
- Trial name
- NCT04316078
- Testing
- patient engagement platform
- Where
- Israel
- Volunteers
- 126 people
- Sponsor
- Sheba Medical Center
Ewings Sarcoma, Non Small Cell Lung Cancer
Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Autologous Vigil™ vaccine expresses rhGMCSF and bi-shRNAfurin from the Vigil™ plasmid. The GMCSF protein is a potent stimulator of the immune system, recruiting immune effectors to the site of intradermal injection and promoting…
- Conditions
- Ewings Sarcoma, Non Small Cell Lung Cancer, Liver Cancer
- Trial name
- NCT01061840
- Testing
- Vigil™
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Gradalis, Inc.
Carcinoma, Neuroendocrine
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
Neuroendocrine tumours (NETs) are rare, slow growing, and diagnosis is often delayed with advanced metastases at presentation. In select patient populations, radioisotope therapy with Lutetium-177 (Lu-DOTA-TATE) has been shown to…
- Trial name
- NCT01876771
- Testing
- [177]Lu-DOTA-TATE
- Where
- Canada
- Volunteers
- 413 people
- Sponsor
- AHS Cancer Control Alberta
Desmoplastic/Nodular Medulloblastoma, Medulloblastoma
Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma
This phase II trial studies how well combination chemotherapy works in treating younger patients with newly diagnosed, non-metastatic desmoplastic medulloblastoma.
- Conditions
- Desmoplastic/Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma With Extensive Nodularity, Nevoid Basal Cell Carcinoma Syndrome
- Trial name
- NCT02017964
- Testing
- Carboplatin, Cognitive Assessment, Cyclophosphamide
- Where
- 173 sites in United States, Australia and 2 more
- Volunteers
- 26 people
- Sponsor
- Children's Oncology Group
Prostate Cancer
A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer
Patients eligible for hormone ablation therapy who are prescribed Firmagon will be followed for a maximum of 3 years to estimate the progression free survival.
- Trial name
- FAST-NL (NCT01215526)
- Where
- 47 sites in Netherlands
- Volunteers
- 274 people
- Sponsor
- Ferring Pharmaceuticals
Head and Neck Squamous Cell Carcinoma, Human Papillomavirus
The Princess Alexandra Hospital and the QIMR Berghofer Medical Research Institute Head and Neck Cancer Study
This study is designed to refine the aetiological causes of cancers of the head and neck and investigate the ways in which human papillomavirus and life-style factors cause head and neck cancers.
- Trial name
- NCT02126189
- Where
- Australia
- Volunteers
- 600 people
- Sponsor
- Queensland Centre of Excellence for Head and Neck Cancer
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating…
- Conditions
- Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
- Trial name
- NCT03091660
- Testing
- BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine
- Where
- 174 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- SWOG Cancer Research Network
Renal Cell Carcinoma, Zero Ischemia
Zero Ischemia Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage
To evaluate the feasibility and efficiency of zero ischemia laparoscopic radio frequency ablation assisted enucleation of T1a renal cell carcinoma in comparison with the conventional laparoscopic partial nephrectomy.
- Trial name
- NCT01838720
- Testing
- zero ischemia laparoscopic RFA assisted TE, ischemia
- Where
- China
- Volunteers
- 90 people
- Sponsor
- RenJi Hospital
Unrecognized Condition
Air Dissection in Percutaneous Radiofrequency Ablation of T1a Renal Cell Carcinoma
The investigators aimed to evaluate the feasibility and safety of using ambient air to protect against thermal injury during RadioFrequency Ablation (RFA) for Renal Cell Carcinoma (RCC) based on data from cases at their institute.
- Trial name
- NCT03395379
- Testing
- RFA
- Volunteers
- 90 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Hepatocellular Carcinoma
Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma
Combination immunotherapy is currently the standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT07091942
- Where
- Taiwan
- Volunteers
- 243 people
- Sponsor
- National Taiwan University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.